General Electric on Tuesday unveiled an exclusive alliance with Geron, the US biotechnology company, which could lead to the first significant commercial application of stem cells as soon as next year.

GE Healthcare will develop Geron’s expertise to build tests for medicines derived from human embryonic stem cells. The tests are designed to identify any toxic effects of experimental medicines, and will be sold to drug developers.